MSI-High Metastatic Hormone-Receptor-Positive Breast Cancer Responding to Pembrolizumab

Patient Info: Anonymized, female, 40s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative; MSI-high; BRCA mutation-negative

Metastatic Site: bone, para-aortic lymph nodes, brain

Pembrolizumab produced marked improvement in metastatic bone and nodal disease. After 1 year it was stopped because of appetite loss; 8 months later she was symptom-free and back at work on endocrine therapy, although asymptomatic brain metastases were documented.

PubMed CentralRead more →

At 41, a Tumor Test Supported Chemotherapy for Rare Neuroendocrine Breast Cancer

Patient Info: Anonymized, Female, 40s

Biomarkers: Chromogranin strongly positive; synaptophysin strongly positive; ER score 270; PR score 75; HER2-negative; Ki-67 60%; Oncotype DX Recurrence Score 41

A 41-year-old with a small, node-negative neuroendocrine breast tumor had an Oncotype DX score of 41, supporting chemotherapy despite otherwise early features.

PubMed CentralRead more →

Left Breast Cancer in a BRCA2 Carrier Treated With Mastectomy, Chemotherapy, and an Arm Port

Patient Info: Anonymized, female, Under 40

Biomarkers: Hormone receptor-positive; HER2-negative; pathogenic BRCA2 variant

At 17 months after surgery, she was free from disease and reported good quality of life and satisfaction with reconstruction and the arm port.

PubMed CentralRead more →

Occult Right Breast Cancer Found During BRCA2 Risk-Reducing Mastectomy

Patient Info: Anonymized, female, Under 40

Biomarkers: Hormone receptor-positive; HER2-negative; pathogenic BRCA2 variant

At the overall 17-month follow-up after bilateral surgery, she was free from disease.

PubMed CentralRead more →

Stage IV BRCA Breast Cancer: Dena's Patient Story

Patient Info: Dena Ofengeim, Under 40 | Stage IV

Biomarkers: Hormone receptor-positive; BRCA mutation

Metastatic Site: spine

Dena improved rapidly after treatment, regained her mobility, returned to an active life, and remained on therapy for metastatic breast cancer.

Dana-FarberRead more →

Hormone-Receptor-Positive Breast Cancer Treated in 1996 Before a Later Separate Primary

Patient Info: Anonymized, female

Biomarkers: Hormone receptor-positive

The later tumor in the same breast was assessed as a separate primary rather than a late recurrence of the 1996 cancer.

PubMed CentralRead more →

Metastatic breast cancer: three years in remission with T-DM1 (Kadcyla) treatment

Patient Info: Anonymized, Female | Stage IV

Biomarkers: HER2-positive; hormone receptor-positive

Metastatic Site: liver; spine / bone

T-DM1 produced a complete clinical and radiological response after 7 cycles, sustained for 41 months and 60 cycles while treatment continued.

PubMed CentralRead more →

Stage III Inflammatory Breast Cancer: Nikki's Patient Story

Patient Info: Nikki, Female, 40s | Stage III

Biomarkers: Hormone-positive

As of July 2023, Nikki had completed 7 chemotherapy rounds for Stage III inflammatory hormone-positive breast cancer, had no sign of distant spread on PET scans, and was preparing for single mastectomy, radiation, and long-term hormone therapy.

The Patient StoryRead more →

Stage III HER2-Positive Inflammatory Breast Cancer: Nikki's Patient Story

Patient Info: Nikki, Female | Stage III

Biomarkers: HER2-positive; hormone receptor-positive

After 7 chemotherapy rounds, imaging showed no visible disease, but the team expected possible microscopic cancer. A single mastectomy, radiation and long-term hormone therapy were still planned, so she was not classified as cancer-free.

The Patient StoryRead more →

Reconstructive surgery technique fixes tissue death after mastectomy

Patient Info: Anonymized, Female

Biomarkers: Hormone receptor-positive in both breast cancers

The reconstructive wound was completely healed at 2 months, and she continued tamoxifen with ongoing follow-up.

PubMed CentralRead more →

HER2-positive breast cancer on hemodialysis: partial response to T-DM1 then no metabolically active disease

Patient Info: Anonymized, Female, 60s | Stage II

Biomarkers: Hormone receptor-positive; HER2/neu-positive; E-cadherin-positive; Ki-67 55-60%; luminal B type

As of March 2023, after 12 total cycles of T-DM1 and modified radical mastectomy, PET-CT showed no metabolically active disease, and she continued endocrine therapy and dialysis.

PubMed CentralRead more →

Stage IV HR-Positive Breast Cancer: Bethany's Patient Story

Patient Info: Bethany, Female, Under 40 | Stage IV

Biomarkers: ER-positive / hormone-positive

Metastatic Site: Liver; bones; lymph nodes; stomach

As of December 2022, Bethany was living with Stage IV metastatic breast cancer after recurrence to the liver, bones, lymph nodes, and stomach, and was on lifelong maintenance treatment after disease shrinkage.

The Patient StoryRead more →

Breast Cancer: Mary's Survivor Story

Patient Info: Mary Richichi, female, 70+

Biomarkers: hormone receptor-positive

Mary’s breast cancer was described as under control and in remission after treatment.

Dana-FarberRead more →

Stage IV PIK3CA Breast Cancer: Abigail's Patient Story

Patient Info: Abigail, Female, Under 40 | Stage IV

Biomarkers: Hormone-positive breast cancer with PIK3CA mutation and germline ATM mutation; later PD-L1 somatic change reported. HER2 not stated.

Metastatic Site: Bone, including femurs, spine, and humeri; later liver

As of October 2022, Abigail was living with Stage IV hormone-positive metastatic breast cancer after years of treatment, bone-dominant disease that later involved the liver, targeted therapies, genomic testing, and advocacy around clinical trials and patient research participation.

The Patient StoryRead more →

Stage III Breast Cancer: Christal's Survivor Story

Patient Info: Christal Love, Female, Under 40 | Stage III

Biomarkers: hormone-positive; HER2-negative

After chemotherapy complications, surgery, radiation, later preventive removal of the other breast and reconstruction, Christal remained cancer-free for more than 5 years as of June 2022.

City of HopeRead more →

Breast Cancer: Brian's Patient Story

Patient Info: Brian Chrobak, Male, Under 40

Biomarkers: Hormone receptor-positive

Brian had completed neoadjuvant chemotherapy and surgery and was preparing to begin radiation and hormone therapy with curative intent. Tests showed no evidence of spread beyond the breast and axillary lymph nodes.

Cleveland ClinicRead more →

Stage III Invasive Ductal Carcinoma: Ximena's Patient Story

Patient Info: Ximena Nardelli, Female, 40s | Stage III

Biomarkers: Hormone receptor-positive

As of February 2020, Ximena had completed mastectomy, 16 chemotherapy sessions, and 21 radiation treatments for Stage III hormone-positive invasive ductal carcinoma and was continuing planned 5-year hormone therapy.

YouTube (ES search)Read more →